Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J5NB
|
|||
| Drug Name |
Pyrazole derivative 25
|
|||
| Synonyms |
PMID26161824-Compound-37
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Patented | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H22Cl2N4OS
|
|||
| Canonical SMILES |
CCC1=NOC(=N1)C2=NN(C(=C2C)C3=CC=C(S3)C#CC4CCCC4)C5=C(C=C(C=C5)Cl)Cl
|
|||
| InChI |
1S/C25H22Cl2N4OS/c1-3-22-28-25(32-30-22)23-15(2)24(31(29-23)20-12-9-17(26)14-19(20)27)21-13-11-18(33-21)10-8-16-6-4-5-7-16/h9,11-14,16H,3-7H2,1-2H3
|
|||
| InChIKey |
NIKGOEACQPFNCK-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cannabinoid receptor 1 (CB1) | Target Info | Antagonist | [1] |
| Target's Patent Info | Cannabinoid receptor 1 (CB1) | Target's Patent Info | [1] | |
| KEGG Pathway | Rap1 signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Retrograde endocannabinoid signaling | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| Pathway Interaction Database | N-cadherin signaling events | |||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Small Ligand GPCRs | ||||
| BDNF signaling pathway | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.